Radhika Shah
Dermatology · Newark, NJNPI 1386105179
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. LEO Pharma Inc. accounts for 80.4% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $54,083, more than ten times the $517 reported in 2023. Among dermatology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $185.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- LEO Pharma Inc.$47K
- Johnson & Johnson$4K
- Galderma Laboratories, L.p.$3K
- UCB, Inc.$2K
- AbbVie$766
- Incyte Corporation$445
- plus $2K from 16 others
Across 9 payments — averaging $6270.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$32K
- Incyte Corporation$14K
- Sanofi Pasteur Inc.$6K
- Eli Lilly$5K
What the payments were for
- Consulting fees$14,69225%
- Speaking & faculty fees$32,06655%
- Travel & lodging$5,0069%
- Food & beverage$6,76812%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| LEO Pharma Inc. | 90 | $47,102 |
| Johnson & Johnson | 43 | $4,035 |
| Galderma Laboratories, L.p. | 13 | $2,536 |
| UCB, Inc. | 14 | $1,635 |
| AbbVie | 43 | $766 |
| Incyte Corporation | 17 | $445 |
| Lilly USA, LLC | 13 | $406 |
| Sun Pharmaceutical Industries Inc. | 21 | $374 |
| E.r. Squibb & Sons, L.L.C. | 5 | $241 |
| Novartis | 9 | $201 |
| Dermavant Sciences, Inc. | 15 | $183 |
| Pfizer | 14 | $166 |
| Sanofi | 3 | $133 |
| Eli Lilly | 1 | $78 |
| Regeneron Healthcare Solutions, Inc. | 3 | $77 |
| Arcutis Biotherapeutics, Inc. | 4 | $67 |
| Amgen | 3 | $64 |
| Almirall LLC | 1 | $28 |
| Organon | 1 | $23 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $23 |
| Cipher Pharmaceuticals US LLC | 1 | $15 |
| Botanix SB Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,611 in reported general payments places this provider in the 90th percentile of 394 dermatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $48,880 |
| OpzeluraRuxolitinib Phosphate | 11 | $20,607 |
| Clobetasol Propionate | 85 | $2,183 |
| Doxycycline Hyclate | 28 | $1,031 |
| Ketoconazole | 66 | $929 |
| Triamcinolone Acetonide | 95 | $818 |
| Fluorouracil | 13 | $817 |
| Tretinoin | 14 | $753 |
| Fluocinonide | 19 | $515 |
| Clindamycin Phosphate | 11 | $288 |
| Hydrocortisone | 37 | $259 |
| Nystatin | 11 | $215 |
| Mupirocin | 16 | $126 |
| Prednisone | 14 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $445 | $20,60711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 394 dermatology providers in New Jersey.
Other dermatology in Newark
- Omar NoorSomerset$4.5M
- Linda Cappiello-LindsleyHoboken$2.3M
- Brian KeeganEast Windsor$1.7M
- Jerry BagelEast Windsor$1.6M
- Mital Patel CohenFlorham Park$799K
- Ronald BernardinVoorhees$688K
- Brian MachlerFlorham Park$346K
- Jeanine DownieMontclair$327K
- Aanand GeriaRutherford$251K
- Jason MillerFreehold$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.